Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4060874 in Healthy Participants
NCT06709820Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LY4060874 in obesity (7 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) up to 22 weeks. Started Dec 2024; status: completed.
02
Drugs
LY4060874
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06709820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709820.